Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection
Xu H, Chen T, Wang W, Wu C, Liu C, Long J, Xu J, Zhang Y, Chen R, Liu L, Yu X. Metabolic tumour burden assessed by 18F-FDG PET/CT associated with serum CA19-9 predicts pancreatic cancer outcome after resection. European Journal Of Nuclear Medicine And Molecular Imaging 2014, 41: 1093-1102. PMID: 24522797, DOI: 10.1007/s00259-014-2688-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Tumor-Associated, CarbohydrateCarcinoma, Pancreatic DuctalFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedMultimodal ImagingPancreatic NeoplasmsPositron-Emission TomographyPostoperative PeriodRadiopharmaceuticalsTomography, X-Ray ComputedTreatment OutcomeTumor BurdenConceptsSerum CA19-9 levelsRecurrence-free survivalMetabolic tumor volumeCA19-9 levelsMetabolic tumor burdenPancreatic ductal adenocarcinomaResectable pancreatic ductal adenocarcinomaTumor burdenOverall survivalTumor sizePancreatic ductal adenocarcinoma patientsSerum CA19-9Predicting overall survivalPancreatic cancer outcomesOperating characteristic analysisPredictive of outcomePET/CT examinationRadical pancreatectomyTumor volumeCA19-9Predicting OSSurrogate markerDuctal adenocarcinomaTLGMultivariate analysis